|Bid||2.1600 x 900|
|Ask||2.4700 x 800|
|Day's Range||2.1500 - 2.2500|
|52 Week Range||1.7700 - 13.5000|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FREEHOLD, N.J., June 18, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that it expects to be added to the Russell 3000® Index, based on a preliminary list of additions posted June 7, 2019. Final inclusion in the Russell 3000® Index will be determined following completion of the annual Russell US Indexes Reconstitution, which occurs after the US equity markets close on Friday, June 28, 2019. Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against the Russell US Indexes. Membership in the Russell Microcap Index remains in place for one year and provides for automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
FREEHOLD, New Jersey, June 13, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the Company's President and Chief Executive Officer, David Jin. M.D., Ph.D., will participate at the Second International Aesthetic Industry Conference in Chengdu, China, the largest scale of its kind across all of Asia.
FREEHOLD, New Jersey, June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major milestone in bio-production standardization of clinical-grade stem cell derived exosomes. The standardized procedure was a direct result of the previously announced co-development program at Weill Cornell Medicine with Yen-Michael Hsu, M.D., Ph.D. as principal investigator. The process has been co-developed and operated within Weill Cornell's cGMP-certified cell therapy facility jointly accredited under Foundation of Accreditation for Cellular Therapy (FACT), American Association of Blood Banking (AABB), College of American Pathologists (CAP), as well as Clinical Laboratory Improvement Amendment (CLIA).
MIT Professors Robert S. Langer and Shuguang Zhang as Co-Principal Investigators Plan to Utilize Innovative “QTY Code" Modified Proteins as Novel Therapeutic Targets FREEHOLD,.
FREEHOLD, NJ / ACCESSWIRE / April 25, 2019 / Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has entered into a purchase agreement with several institutional investors for the purchase of 1,714,288 units in a registered direct offering, for expected gross proceeds of approximately $6 million before placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund its core technology platform development and clinical studies in exosome-based liquid biopsy and regenerative therapeutics, next-generation multi-targeted CAR-T immunotherapy, co-development projects with MIT and Weill Cornell, as well as for working capital and other general corporate purposes.
FREEHOLD, NJ / ACCESSWIRE / April 24, 2019 / Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Robert S. Langer, Sc.D., to its Scientific and Clinical Advisory Board. Dr. Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (M.I.T.) (being an Institute Professor is the highest honor that can be awarded to a faculty member).
Co-organized with the Regenerative Medicine Foundation Concurrent with the 7th Annual Lu Daopei Hematology Forum FREEHOLD, NJ / ACCESSWIRE / April 17, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading ...
FREEHOLD, NJ / ACCESSWIRE / April 8, 2019 / Avalon GloboCare Corp. (AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today the addition of Yue "Charles" Li to the Company's Board of Directors. Mr. Li qualifies as an independent director and will serve on the acquisition task force committee. The Company also announced the reappointment of Meng Li to the Company's Board of Directors.
FREEHOLD, NJ / ACCESSWIRE / March 6, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of innovative and transformative cell-based technologies ...
AVA-101 designed to enhance efficacy and overcome safety challenges of current CAR-T immune-oncology therapeutics AVA-101 represents a first-in-class transposon-based Chimeric.
Angiogenic exosomes containing angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes. Results from Avalon’s.
FREEHOLD, N.J., Feb. 04, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of cell-based technologies and.
Every now and then, a stock seemingly explodes out of nowhere. Right now, Avalon GloboCare (NASDAQ:AVCO) seems to be that stock. AVCO stock finished 2018 at $2.75. That same Avalon GloboCare stock closed Monday at $6.93, after touching $12 last week. Source: Shutterstock It's not at all clear what's driving the huge gains. Indeed, Will Healy wrote last week that the movement in AVCO stock was a mystery. There is an apparently interesting opportunity in the company's efforts in the exosome space. But questions surround how the company is attacking that opportunity -- and why investors value AVCO at some $500 million. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### The AVCO Stock Story Avalon Globocare was incorporated as Global Technologies, and issued its first Form 10-K in February 2016. At the time, the company had 7 million shares outstanding and zero employees. The K cites a plan to develop back office software, which sounds roughly like the business model of Square (NYSE:SQ). * 7 High-Dividend Stocks Yielding More Than 5% (Plus a Bonus) In 2016, the company executed a reverse split and changed its name to Avalon GloboCare. The company that was a software developer now had a multi-pronged medical strategy. AVCO would develop an "Avalon cell" platform, with four different programs. One was a focus on CAR-T immunotherapy; remember that Gilead Sciences (NASDAQ:GILD) bought CAR-T leader Kite Pharma for $12 billion last year. Beyond "Avalon cell," AVCO also noted a potential telemedicine opportunity, and a rehabilitation offering in China. And it cited the potential for M&A, joint venture and consulting opportunities. Last year, the company acquired 60% of GenExosome Technologies for $1.3 million in cash and 500,000 shares. It also acquired property in New Jersey, with rental income contributing to revenue, along with consulting. And this week, GenExosome announced the discovery of the "world's first saliva-based exosomal biomarker," which potentially could be used in detecting and treating oral cancer. If that pans out, the opportunities could be huge, so it does seem like Avalon GloboCare is making some progress. But there are some very real questions here. ### Strategic Questions for Avalon GloboCare The most obvious question surrounding AVCO stock is why, exactly, the company is supposed to be successful. This is a company that closed the third quarter with $3.8 million in cash. That's barely enough to support any of the company's initiatives: indeed, the company has free cash flow of negative $3.6 million in just the first three quarters of this year, per the 10-Q. So why the multiple efforts? And what is Avalon GloboCare's edge in any of them? Meanwhile, the strategy per the most recent 10-K seems to go even further. The company cites an "initial component" of its strategy as "acquiring and/or managing fixed assets including healthcare real estate as well as stem cell banks." This comes after the company - which, again, has less than $4 million in cash - spent over $7 million to purchase, rather than lease, its New Jersey headquarters. The overall strategy here seems unfocused, to say the least. Is the company a consulting firm? A real estate management company? A drug developer? It's not clear. To be sure, Exosome technology in theory has promise: one analyst called the category "the rising star in drug delivery." And Bio-Techne (NASDAQ:TECH) paid $250 million in cash, plus contingent consideration, for Exosome Diagnostics last year. But Avalon GloboCare doesn't even seem to be focusing on that opportunity. And a company that does many things isn't likely to do any of them well. Meanwhile, with less than $4 million in cash, there clearly isn't enough to properly support any of these efforts. That means an AVCO stock offering likely is on the way. But it also suggests that Avalon GloboCare stock could be notably overvalued. ### The Valuation of Avalon GloboCare Stock It's impossible to evaluate AVCO stock through pure fundamental analysis. Revenue outside of property rental is just $370,000 so far this year. But what figures we do have suggest that a stock price near $7 is somewhat foolish. The 60% stake in GenExosome was acquired for $1.3 million in cash and roughly $1 million worth of stock. If that business is driving the recent optimism, why was such a valuable business sold for an implied valuation of $4 million? Avalon GloboCare itself sold stock last year -- at $1.75 and $2.25. Even acknowledging that small-cap companies have to execute offerings at a substantial discount, Avalon GloboCare issued stock at barely one-fourth the current price. Between M&A and the equity offering, nothing AVCO itself has done suggests that the company believes it should be worth roughly $500 million. That's the current market capitalization of AVCO, based on the quarter-end figure of 72.573 million shares outstanding. Investors should note that AVCO -- which hasn't really accomplished anything, and which has significant financial and strategic questions -- now is worth more than Exosome Technologies when it was bought out, even accounting for the present value of the contingent consideration. That seems aggressive for a company with basically one accomplishment of note. That's particularly true given that as recently as 2015 the company was trying to develop software. How the rest of this story will play out is unclear, admittedly. But it does seem already like the absolute best-case scenario is priced in. As of this writing, Vince Martin had no positions in any securities mentioned. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy With High ESG Momentum * 7 Chinese Stocks to Buy Now * 5 Dow Jones Stocks Under Pressure Compare Brokers The post Avalon GloboCare Stock Is an Expensive Mystery appeared first on InvestorPlace.
Study Accepted as Poster Presentation at the 8th Annual Meeting of the International Society for Extracellular Vesicles (ISEV 2019) Publication of PCT Patent Application.
Avalon GloboCare (NASDAQ:AVCO) has garnered investor attention from something rarely seen in AVCO stock: activity. After stagnating in penny-stock territory for the last few months, both trading volume and AVCO itself spiked on January 22. It fell nearly as fast in trading on the next day. No clues as to why this occurred have become known to the public. However, with the previous lack of activity and scant information from the financial statements, investors should remain on the sidelines. Avalon GloboCare provides biotech development and healthcare services. Through telemedicine, rehab and cell platforms they offer healthcare facility management, as well as strategic advisory and outsourcing services in healthcare. Its network encompasses over 100 hospitals and other facilities in both the U.S. and China. Peers such as HCA Healthcare (NYSE:HCA), Universal Health Services (NYSE:UHS), and Teladoc Health (NYSE:TDOC) offer similar services. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### The Spike in AVCO Stock Remains a Mystery AVCO stock launched its IPO in late 2016. As a small-cap company that spent most of its history as a penny stock, it has received little attention until recently. However, a sudden spike in activity has changed this situation. Yesterday, AVCO went up by 124%. Today, it gave up much of that gain, having fallen by about 45%. * 3 Blue-Chip Stocks That Will Power Through Market Turmoil Until mid-January, AVCO stock had seen thin trading volumes. Before mid-January, daily trading volumes rarely exceeded 10,000 shares. Some days saw fewer than 1,000 shares traded. However, trading volumes spiked to 92,300 on the trading day before the massive surge. Then yesterday, over 1.58 million shares exchanged hands. That level of activity continues as AVCO stock falls back to earth. The reason for the sudden interest in AVCO stock remains unclear. The company filed a preliminary prospectus for a mixed-shelf offering of $50 million last week. This would allow Avalon to issue a new security and release shares at their discretion over a three-year period. We might also receive some information from the leadership itself soon. CEO David Jin is scheduled to speak at the World Stem Cell Summit in Miami on Thursday. ### Investors Have Too Little Information to Act on AVCO Stock From what we do know, I find it difficult to recommend AVCO stock. For now, it remains an unproven startup. Even after the recent activity, the market cap stands at just over $500 million. The stock has fallen below $1 per share at times over the last year. Before the sudden surge in activity, AVCO traded just below $3 per share range for six months. From a financial statement perspective, Avalon appears to bring in negligible amounts of revenue. Also, it has lost between $1 to 2 million in each of the last four quarters. The balance sheet also offers little clue of activity, though additional paid in capital rose from $4 million to $23 million over the previous year. However, with few numbers to work with, no news and an uncertain direction, I see no reason to buy AVCO stock at this time. ### The Bottom Line on AVCO Stock The recent movement in AVCO stock serves as a reminder of both the allure and the dangers of such stocks. For most of its history, Avalon GloboCare stock saw little attention or movement. * 7 Stupidly Cheap Stocks to Buy Now The current activity has come from seemingly nowhere. The company has not released any significant information in the last week. Financial statements also offer few clues. The CEO may reveal more at an upcoming conference. However, with little financial or news-related information, investors should stay away from AVCO stock. As of this writing, Will Healy is long TDOC. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Consumer Stocks to Buy for Income * 7 Dark Horse Stocks You Really Need to Look at for 2019 * 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Mystery Surrounds the Sudden Activity in AVCO Stock appeared first on InvestorPlace.
NEW YORK , Jan. 16, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...
FREEHOLD, N.J., Jan. 15, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that its President and Chief.
FREEHOLD, N.J., Jan. 03, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that the Company and its wholly.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
FREEHOLD, N.J., Dec. 19, 2018 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that it will.
FREEHOLD, N.J., Nov. 13, 2018 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a.
FREEHOLD, N.J., Nov. 05, 2018 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced its common stock.